NCT01970358 — Patrick Ott, MD, PhD neoantigen vaccine trial
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Registry record
| Registry ID | NCT01970358 ↗ |
|---|---|
| Lead sponsor | Patrick Ott, MD, PhD |
| Collaborators | — |
| Phase | Phase 1 |
| Status | Completed |
| Indication | Melanoma |
| Enrollment | 15 participants |
| Start date | 2014-04 |
| Primary completion | 2015-09 |
| Last registry update | 29 Dec 2025 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT01970358), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT01970358?
NCT01970358 (A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma) is registered on ClinicalTrials.gov as Phase 1, sponsored by Patrick Ott, MD, PhD.
Is NCT01970358 recruiting?
As of the 2025-12-29 registry update, NCT01970358 is listed as "Completed". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT01970358?
The lead sponsor is Patrick Ott, MD, PhD.
What condition does NCT01970358 study?
The registered condition is Melanoma. Primary completion is listed as 2015-09.
Are results available for NCT01970358?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT01970358.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.